We are live on ! Find out more
AMED

Amedisys

Delisted

AMED was delisted on the 14th of August, 2025.

317 hedge funds and large institutions have $3.47B invested in Amedisys in 2019 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 117 increasing their positions, 107 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 43

7% more funds holding

Funds holding: 297317 (+20)

9% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 107

2% more capital invested

Capital invested by funds: $3.41B → $3.47B (+$55.8M)

4.06% less ownership

Funds ownership: 92.17%88.11% (-4.1%)

61% less call options, than puts

Call options by funds: $10.3M | Put options by funds: $26.4M

Holders
317
Holders Change
+20
Holders Change %
+6.73%
% of All Funds
6.86%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
64
Increased
117
Reduced
107
Closed
43
Calls
$10.3M
Puts
$26.4M
Net Calls
-$16.1M
Net Calls Change
-$18M
Name Holding Trade Value Shares
Change
Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$29.6M +$12.9M +102,700 +75%
Millennium Management
27
Millennium Management
New York
$29.2M +$1.79M +14,254 +6%
Bank of America
28
Bank of America
North Carolina
$29M -$423K -3,369 -1%
Marshall Wace
29
Marshall Wace
United Kingdom
$27.2M +$20.6M +163,842 +289%
Loomis, Sayles & Company
30
Loomis, Sayles & Company
Massachusetts
$26.8M -$1.47M -11,745 -5%
O
31
OppenheimerFunds
New York
$26.3M +$5.61M +44,699 +27%
Deutsche Bank
32
Deutsche Bank
Germany
$23.4M -$16.2M -129,089 -40%
Renaissance Technologies
33
Renaissance Technologies
New York
$23.3M -$11.7M -93,000 -33%
JIM
34
Jupiter Investment Management
United Kingdom
$23.2M -$10.1M -80,696 -30%
EVM
35
Eaton Vance Management
Massachusetts
$23M +$1.76M +13,994 +8%
Goldman Sachs
36
Goldman Sachs
New York
$22.9M -$14.2M -113,091 -38%
AQR Capital Management
37
AQR Capital Management
Connecticut
$20M +$5.63M +44,819 +38%
Robeco Institutional Asset Management
38
Robeco Institutional Asset Management
Netherlands
$18.9M +$2.51M +19,983 +15%
Allianz Asset Management
39
Allianz Asset Management
Germany
$18.6M +$8.49M +67,666 +81%
Principal Financial Group
40
Principal Financial Group
Iowa
$18.1M -$13.7M -109,509 -43%
Russell Investments Group
41
Russell Investments Group
United Kingdom
$16.6M +$5.12M +40,769 +42%
TCIM
42
TIAA CREF Investment Management
New York
$16M +$2.43M +19,357 +18%
GLA
43
Great Lakes Advisors
Illinois
$15.1M -$2.24M -17,822 -13%
SEI Investments
44
SEI Investments
Pennsylvania
$14.6M -$1.6M -12,759 -10%
AAMU
45
Amundi Asset Management US
Massachusetts
$14.1M -$46.6K -371 -0.3%
AL
46
AJO LP
Pennsylvania
$13.6M +$13.4M +106,445 +3,004%
Federated Hermes
47
Federated Hermes
Pennsylvania
$12.4M -$9.32M -74,246 -42%
Axa
48
Axa
France
$12.3M -$2.01M -16,000 -14%
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$12M +$2.8M +22,300 +30%
CAM
50
ClariVest Asset Management
California
$11.8M -$658K -5,239 -5%

AMED Hedge Fund Activity: Q1 2019 in Review

317 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q1 2019, worth a combined $3.47B — up 1.6% from $3.41B a quarter earlier.

Buyers outnumbered sellers: 64 funds opened new AMED positions and 43 closed out — a net gain of 21 holders — while 117 added to existing stakes and 107 trimmed.

The largest buyer was Man Group, adding an estimated $22.4M. The largest seller was BlackRock, cutting an estimated $104M.

  • 317 institutional investors held Amedisys (AMED) as of Q1 2019, up from 297 in Q4 2018.
  • Funds reported $3.47B of Amedisys stock for Q1 2019, up 1.6% quarter-over-quarter.
  • 64 funds opened new Amedisys positions in Q1 2019 and 43 closed out, a net change of +21 holders.
  • The largest Amedisys buyer in Q1 2019 was Man Group, an estimated $22.4M added.
  • The largest Amedisys seller in Q1 2019 was BlackRock, an estimated $104M sold.

Based on aggregated 13F filings for Q1 2019.